Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ADMA 
ADMA Biologics Inc (ADMA)
Top performer
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/07/2025: ADMA (5-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $29.06
1 Year Target Price $29.06
| 2 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 144.75% | Avg. Invested days 46 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 08/07/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.43B USD | Price to earnings Ratio 22.07 | 1Y Target Price 29.06 |
Price to earnings Ratio 22.07 | 1Y Target Price 29.06 | ||
Volume (30-day avg) 3 | Beta 0.38 | 52 Weeks Range 13.50 - 25.67 | Updated Date 08/6/2025 |
52 Weeks Range 13.50 - 25.67 | Updated Date 08/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.84 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-06 | When - | Estimate 0.1533 | Actual 0.145 |
Profitability
Profit Margin 45.01% | Operating Margin (TTM) 30.38% |
Management Effectiveness
Return on Assets (TTM) 22.06% | Return on Equity (TTM) 78.45% |
Valuation
Trailing PE 22.07 | Forward PE 28.99 | Enterprise Value 4536789304 | Price to Sales(TTM) 9.63 |
Enterprise Value 4536789304 | Price to Sales(TTM) 9.63 | ||
Enterprise Value to Revenue 9.88 | Enterprise Value to EBITDA 28.21 | Shares Outstanding 238734000 | Shares Floating 233959561 |
Shares Outstanding 238734000 | Shares Floating 233959561 | ||
Percent Insiders 2.57 | Percent Institutions 91.74 |
Upturn AI SWOT
ADMA Biologics Inc
Company Overview
History and Background
ADMA Biologics, Inc. was founded in 2004. It's a biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. A significant milestone was FDA approval and commercialization of its immune globulin products.
Core Business Areas
- Plasma-Derived Biologics: ADMA manufactures and commercializes plasma-derived biologics, primarily immune globulins, for treating immune deficiencies.
- Plasma Collection: ADMA operates its own FDA-approved plasma collection centers, ensuring a reliable supply of source plasma.
Leadership and Structure
ADMA Biologics is led by Adam Grossman (President and CEO). The organizational structure includes departments for manufacturing, research and development, commercial operations, and plasma operations. The Board of Directors oversees the company's strategic direction.
Top Products and Market Share
Key Offerings
- BIVIGAM: A plasma-derived intravenous immune globulin (IVIG) used to treat primary immunodeficiency diseases (PIDD). Competitors include Grifols (GRFS), CSL Behring (CSLLY), Takeda (TAK), and Kedrion Biopharma. Market share and revenue for BIVIGAM specifically are not publicly disaggregated, but it contributes significantly to ADMA's total revenue. The IVIG market is fragmented.
- ASCENIV: A plasma-derived IVIG indicated for the treatment of PIDD in adults and adolescents. Competitors are the same as BIVIGAM: Grifols (GRFS), CSL Behring (CSLLY), Takeda (TAK), and Kedrion Biopharma. Similar to BIVIGAM, specific market share data for ASCENIV is not publicly available, but it's a core product.
- NABI-HB: A hyperimmune globulin indicated for providing passive immunity to hepatitis B infection. Competitors include Grifols (GRFS) HyperHEP B. ADMA acquired this product which bolstered their portfolio to treat infectious diseases.
Market Dynamics
Industry Overview
The plasma-derived therapies market is growing, driven by increasing prevalence of immune deficiencies, advancements in diagnostics, and expanded therapeutic applications. The industry is highly regulated and requires significant capital investment.
Positioning
ADMA Biologics is a smaller player compared to industry giants like Grifols and CSL Behring. Its competitive advantage lies in its focus on hyperimmune globulins and its vertically integrated plasma collection network.
Total Addressable Market (TAM)
The global immunoglobulins market is projected to reach approximately $17 billion by 2028. ADMA's TAM is within the PIDD and hyperimmune globulin segments of this broader market. Their market position allows them to capture a small, but growing segment of the overall TAM.
Upturn SWOT Analysis
Strengths
- Vertically integrated plasma collection network
- FDA-approved products for niche indications
- Focus on hyperimmune globulins
- Experienced management team
Weaknesses
- Smaller scale compared to major competitors
- Reliance on a limited number of products
- High operating expenses
- Historically unprofitable
Opportunities
- Expanding plasma collection capacity
- Developing new plasma-derived therapies
- Acquiring complementary products or technologies
- Geographic expansion
Threats
- Competition from larger players
- Pricing pressures
- Regulatory changes
- Plasma supply disruptions
Competitors and Market Share
Key Competitors
- GRFS
- CSLLY
- TAK
Competitive Landscape
ADMA operates in a competitive market dominated by larger players. ADMA's advantages include its vertically integrated plasma collection network and focus on niche indications, while its disadvantages include its smaller scale and limited product portfolio.
Growth Trajectory and Initiatives
Historical Growth: ADMA Biologics has experienced revenue growth in recent years, driven by increased sales of its plasma-derived products and expansion of its plasma collection network.
Future Projections: Analysts project continued revenue growth for ADMA Biologics, driven by increasing demand for its products and expansion of its plasma collection capacity. Profitability is expected to improve in the coming years.
Recent Initiatives: Recent strategic initiatives include expanding plasma collection center operations, optimizing manufacturing processes, and pursuing new product development opportunities.
Summary
ADMA Biologics is a growing biopharmaceutical company focused on plasma-derived therapies with FDA approved products. The vertically integrated plasma collection network is a significant strength. Profitability remains a key challenge. Competition is intense. They must watch larger industry player activities.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Analyst Reports
- Industry Publications
- Company Website
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered financial advice. Market conditions and company performance are subject to change. This analysis is based on publicly available information and limited assumptions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ADMA Biologics Inc
Exchange NASDAQ | Headquaters Ramsey, NJ, United States | ||
IPO Launch date 2013-10-17 | Co-Founder, President, CEO & Director Mr. Adam S. Grossman | ||
Sector Healthcare | Industry Biotechnology | Full time employees 685 | Website https://www.admabiologics.com |
Full time employees 685 | Website https://www.admabiologics.com | ||
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.